Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.
|Articles|March 21, 2013
Quality, safety concerns
Advertisement
To the Editor:
I am a licensed optician in the state of New York and a member of the Opticians Alliance of New York. Our membership has a concern regarding the selling of contact lenses over the Internet.
The contact lens patient feels a savings can be made on their part, but at the same time the patient is taking a chance by hoping the contact lens Rx is filled correctly and by a licensed professional.
Has there been an investigation by either the FDA or FTC on this issue?
Anthony Rebaldo
New York
Advertisement
Related to this article
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The screen time question: What to ask and when to look deeper
2
AAOpt 2026: Current controversies in macular hole diagnosis, management
3
AAOpt 2026: Jeffrey Walline, OD, PhD, on his conference takeaways
4
FAQ: What clinicians should know as SYD-101 heads to FDA advisory committee
5